C
Centessa Pharmaceuticals plc (CNTA)
NMS – Real Time Price. Currency in USD
39.61
+0.02 (0.05%)
At close: May 12, 2026, 4:00 PM EDT
39.56
-0.05 (-0.13%)
After-hours: May 12, 2026, 6:52 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
39.61
+0.02 (0.05%)
At close: May 12, 2026, 4:00 PM EDT
39.56
-0.05 (-0.13%)
After-hours: May 12, 2026, 6:52 PM EDT
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Name | Position |
|---|---|
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer |
| Dr. Kimberly A. McCormick Pharm.D. | Senior Vice President of Regulatory Affairs & Medical Writing |
| Dr. Mario Alberto Accardi Ph.D. | CEO & Director |
| Dr. Stephen J. Kanes M.D., Ph.D. | Head of R&D and Chief Medical Officer |
| Mr. Iqbal J. Hussain L.L.B. | Chief Legal Officer, Chief Compliance Officer & Company Secretary |
| Ms. Charlene Stoudt | Senior Vice President of Clinical Development Operations |
| Ms. Karen M. Anderson | Chief People Officer |
| Ms. Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations & Corporate Communications |
| Ms. Tia L. Bush | Chief Technology & Quality Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | DEFM14A | d148719ddefm14a.htm |
| 2026-05-05 | 10-Q | cnta-20260331.htm |
| 2026-04-29 | DEF 14A | cnta-20260428.htm |
| 2026-04-29 | ARS | centessaars-123125.pdf |
| 2026-04-17 | PREM14A | d148719dprem14a.htm |
| 2026-04-13 | DEFA14A | d20845ddefa14a.htm |
| 2026-03-31 | DEFA14A | d86726ddefa14a.htm |
| 2026-02-13 | 8-K | d932267d8k.htm |
| 2026-01-07 | 8-K/A | d51805d8ka.htm |
| 2025-12-11 | 8-K | d933269d8k.htm |